Biofrontera prelim April revenue up 400%

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of April 2021.

The Company’s preliminary, unaudited revenue from product sales in April 2021 amounted to approximately EUR 2,491 thousand, compared to EUR 492 thousand in April 2020, an increase of 406%. Total revenue for the month of April 2020 was EUR 6,602 thousand, whereby April 2020 included a one-time down payment of EUR 6,000 thousand from Maruho Co., Ltd as part of a license and supply agreement.

Preliminary revenues from product sales in the US were around EUR 1,821 thousand compared to EUR 333 thousand in April 2020, an increase of 447%. In Germany, revenues from product sales amounted to approximately EUR 441 thousand, compared to EUR 143 thousand in April 2020, an increase of 208%. In the rest of Europe, the Company generated product sales of around EUR 229 thousand, compared to EUR 17 thousand in April 2020, a plus of 1,247%.

Preliminary unaudited revenues

	April			January - April
in EUR thousands	2021	2020	2019	2021	2020	2019
USA	1,821	333	1,767	5.631	4,513	6,939
Germany	441	143	353	1,845	1,453	1,425
Europe (ex Germany)	229	17	191	493	836	755
Total revenue from product sales	2,491	492	2,311	7,969	6,802	9,119
Revenues from R&D projects and license payments	-	6,110	44	-	6,273	44
Total revenue	2,491	6,602	2,355	7,969	13,075	9,163

For better comparability, the Company also included the monthly sales performance before the pandemic in 2019. Compared to 2019, total product sales in 2021 were up 8% in all markets. In detail, April 2021 sales were up 3% in the U.S., 25% in Germany and 20% in the rest of the European markets compared to April 2019.

The sales increase compared to the previous year already perceived since mid-March 2021, especially in our most important sales market, the USA, continued strongly in April 2021. This indicates a significant recovery of the COVID-19 situation in the USA as well as in Germany - presumably also due to the high vaccination rates.

https://finance.yahoo.com/news/biofrontera-reports-preliminary-revenue-month-112300200.html